NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00688740,Docetaxel in Node Positive Adjuvant Breast Cancer,https://clinicaltrials.gov/study/NCT00688740,TAX316,COMPLETED,The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable breast cancer patients with positive axillary lymph nodes.,YES,Breast Cancer,DRUG: Docetaxel|DRUG: 5-fluorouracil|DRUG: Doxorubicin|DRUG: Cyclophosphamide,"Number of Participants With Disease-Free Survival Events, Disease-Free Survival (DFS)- are defined as local, regional or metastatic relapse or the date of second primary cancer or death from any cause whichever occurs first., up to 10 year follow-up","Number of Participants With Overall Survival Events, Overall Survival - time from the date of randomization up to the date of death of any cause., up to 10 year follow-up|Number of Participants With Second Primary Malignancies (Toxicity), Toxicity (second primary malignancies)- defined as histopathologically proven cancer, excluding nonmelanomatous skin cancer, in situ carcinoma of the cervix, and in situ carcinoma of the breast., up to 10 year follow-up",,Sanofi,Cancer International Research Group (CIRG),FEMALE,"ADULT, OLDER_ADULT",PHASE3,1491,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,EFC6041|XRP6976D-316|BCIRG001,1997-06,2010-01,2010-01,2008-06-03,2011-02-14,2011-02-16,"Sanofi-Aventis Administrative Office, Bridgewater, New Jersey, 08807, United States|Sanofi-Aventis Administrative Office, Buenos Aires, Argentina|Sanofi-Aventis Administrative Office, Wien, Austria|Sanofi-Aventis Administrative Office, Sao Paulo, Brazil|Sanofi-Aventis Administrative Office, Laval, Canada|Sanofi-Aventis Administrative Office, Praha, Czech Republic|Sanofi-Aventis Administrative Office, Cairo, Egypt|Sanofi-Aventis Administrative Office, Paris, France|Sanofi-Aventis Administrative Office, Berlin, Germany|Sanofi-Aventis Administrative Office, Athens, Greece|Sanofi-Aventis Administrative Office, Budapest, Hungary|sanofi-aventis Administrative office, Natanya, Israel|Sanofi-Aventis Administrative Office, Warszawa, Poland|Sanofi-Aventis Administrative Office, Porto Salvo, Portugal|Sanofi-Aventis Administrative Office, Bratislava, Slovakia|Sanofi-Aventis Administrative Office, Midrand, South Africa|Sanofi-Aventis Administrative Office, Barcelona, Spain|Sanofi-Aventis Administrative Office, Bromma, Sweden|Sanofi-aventis adminsitrative office, Guildford Surrey, United Kingdom|Sanofi-aventis administrative office, Montevideo, Uruguay",
